Pulse Biosciences (PLSE) to Release Earnings on Tuesday

Key Points

• Pulse Biosciences will release its Q2 2025 earnings results on Tuesday, August 12th, with analysts expecting a loss of ($0.26) per share.
• The company's stock price increased by 1.7% to $15.33, although it trades below its 200-day moving average of $17.12.
• Oppenheimer has initiated coverage on Pulse Biosciences, giving it an "outperform" rating and a price target of $22.00.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results after the market closes on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.26) per share for the quarter.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.25) earnings per share for the quarter.

Pulse Biosciences Stock Up 1.7%

NASDAQ PLSE traded up $0.26 during trading hours on Tuesday, reaching $15.33. The company's stock had a trading volume of 61,510 shares, compared to its average volume of 171,926. The firm has a fifty day simple moving average of $15.78 and a 200-day simple moving average of $17.12. Pulse Biosciences has a 52 week low of $13.60 and a 52 week high of $25.00.

Insider Buying and Selling

In other Pulse Biosciences news, CTO Darrin Uecker sold 15,000 shares of Pulse Biosciences stock in a transaction on Thursday, June 12th. The shares were sold at an average price of $16.40, for a total transaction of $246,000.00. Following the transaction, the chief technology officer directly owned 137,872 shares of the company's stock, valued at $2,261,100.80. The trade was a 9.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 71.50% of the company's stock.

Hedge Funds Weigh In On Pulse Biosciences

An institutional investor recently bought a new position in Pulse Biosciences stock. Jane Street Group LLC acquired a new stake in Pulse Biosciences, Inc (NASDAQ:PLSE - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The fund acquired 20,105 shares of the company's stock, valued at approximately $323,000. 76.95% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Oppenheimer began coverage on shares of Pulse Biosciences in a research report on Monday, July 7th. They set an "outperform" rating and a $22.00 price objective for the company.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.